The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Osteitis Deformans

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Osteitis Deformans


Psychiatry related information on Osteitis Deformans


High impact information on Osteitis Deformans


Chemical compound and disease context of Osteitis Deformans


Biological context of Osteitis Deformans


Anatomical context of Osteitis Deformans


Gene context of Osteitis Deformans


Analytical, diagnostic and therapeutic context of Osteitis Deformans


  1. Response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia in human subjects. Bilezikian, J.P., Canfield, R.E., Jacobs, T.P., Polay, J.S., D'Adamo, A.P., Eisman, J.A., DeLuca, H.F. N. Engl. J. Med. (1978) [Pubmed]
  2. Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Khairi, M.R., Altman, R.D., DeRosa, G.P., Zimmermann, J., Schenk, R.K., Johnston, C.C. Ann. Intern. Med. (1977) [Pubmed]
  3. Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget's disease of bone. Ciani, B., Layfield, R., Cavey, J.R., Sheppard, P.W., Searle, M.S. J. Biol. Chem. (2003) [Pubmed]
  4. Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry. Meunier, P.J., Chapuy, M.C., Delmas, P., Charhon, S., Edouard, C., Arlot, M. Am. J. Med. (1987) [Pubmed]
  5. Monoclonal antibody assay for free urinary pyridinium cross-links. Gomez, B., Ardakani, S., Evans, B.J., Merrell, L.D., Jenkins, D.K., Kung, V.T. Clin. Chem. (1996) [Pubmed]
  6. Etiologic factors in Paget's disease of bone. Reddy, S.V. Cell. Mol. Life Sci. (2006) [Pubmed]
  7. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Hughes, A.E., Ralston, S.H., Marken, J., Bell, C., MacPherson, H., Wallace, R.G., van Hul, W., Whyte, M.P., Nakatsuka, K., Hovy, L., Anderson, D.M. Nat. Genet. (2000) [Pubmed]
  8. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. Krane, S.M., Kantrowitz, F.G., Byrne, M., Pinnell, S.R., Singer, F.R. J. Clin. Invest. (1977) [Pubmed]
  9. Hazards of gallium for Paget's disease of bone. Matkovic, V., Apseloff, G., Shepard, D., Gerber, N. Lancet (1990) [Pubmed]
  10. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Yates, A.J., Percival, R.C., Gray, R.E., Atkins, R.M., Urwin, G.H., Hamdy, N.A., Preston, C.J., Beneton, M.N., Russell, R.G., Kanis, J.A. Lancet (1985) [Pubmed]
  11. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Douglas, D.L., Duckworth, T., Russell, R.G., Kanis, J.A., Preston, C.J., Preston, F.E., Prenton, M.A., Woodhead, J.S. Lancet (1980) [Pubmed]
  12. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Meunier, P.J., Chapuy, M.C., Alexandre, C., Bressot, C., Edouard, C., Vignon, C., Mathieu, L., Trechsel, U. Lancet (1979) [Pubmed]
  13. Etidronate disodium in the treatment of Paget's disease of bone. Krane, S.M. Ann. Intern. Med. (1982) [Pubmed]
  14. Mithramycin and long remission of Paget's disease of bone. Ryan, W.G., Schwartz, T.B., Fordham, E.W. Ann. Intern. Med. (1980) [Pubmed]
  15. Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis. Warrell, R.P., Bosco, B., Weinerman, S., Levine, B., Lane, J., Bockman, R.S. Ann. Intern. Med. (1990) [Pubmed]
  16. Familial Paget's disease of bone: nonlinkage to the PDB1 and PDB2 loci on chromosomes 6p and 18q in a large pedigree. Good, D., Busfield, F., Duffy, D., Lovelock, P.K., Kesting, J.B., Cameron, D.P., Shaw, J.T. J. Bone Miner. Res. (2001) [Pubmed]
  17. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. Cremers, S.C., Eekhoff, M.E., Den Hartigh, J., Hamdy, N.A., Vermeij, P., Papapoulos, S.E. J. Bone Miner. Res. (2003) [Pubmed]
  18. Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent. Lucas, G.J., Hocking, L.J., Daroszewska, A., Cundy, T., Nicholson, G.C., Walsh, J.P., Fraser, W.D., Meier, C., Hooper, M.J., Ralston, S.H. J. Bone Miner. Res. (2005) [Pubmed]
  19. Cytogenetic investigations of patients on clodronate therapy for Paget's disease of bone. Borgström, G.H., Elomaa, I., Blomqvist, C., Porkka, L. Bone (1987) [Pubmed]
  20. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate. de la Piedra, C., Rapado, A., Díaz Diego, E.M., Díaz Martín, M.A., Aguirre, C., López Gavilanes, E., Díaz Curiel, M. Calcif. Tissue Int. (1996) [Pubmed]
  21. Multicentric giant cell tumor with viral-like inclusions associated with Paget's disease of bone: a case treated by steroid therapy. De Chiara, A., Apice, G., Fazioli, F., Silvestro, P., Carone, G., Manco, A. Oncol. Rep. (1998) [Pubmed]
  22. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hocking, L.J., Lucas, G.J., Daroszewska, A., Mangion, J., Olavesen, M., Cundy, T., Nicholson, G.C., Ward, L., Bennett, S.T., Wuyts, W., Van Hul, W., Ralston, S.H. Hum. Mol. Genet. (2002) [Pubmed]
  23. Hypocalcemic actions of amylin amide in humans. Wimalawansa, S.J., Gunasekera, R.D., Datta, H.K. J. Bone Miner. Res. (1992) [Pubmed]
  24. Frequencies of HLA-A and HLA-B histocompatibility antigens in Paget's disease of bone. Cullen, P., Russell, R.G., Walton, R.J., Whiteley, J. Tissue Antigens (1976) [Pubmed]
  25. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Alvarez, L., Peris, P., Guañabens, N., Vidal, S., Ros, I., Pons, F., Filella, X., Monegal, A., Muñoz-Gomez, J., Ballesta, A.M. Arthritis Rheum. (2003) [Pubmed]
  26. Parathyroid function in Paget's disease of bone. Siris, E.S., Clemens, T.P., McMahon, D., Gordon, A., Jacobs, T.P., Canfield, R.E. J. Bone Miner. Res. (1989) [Pubmed]
  27. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Roux, C., Gennari, C., Farrerons, J., Devogelaer, J.P., Mulder, H., Kruse, H.P., Picot, C., Titeux, L., Reginster, J.Y., Dougados, M. Arthritis Rheum. (1995) [Pubmed]
  28. Bisphosphonate space measurement in Paget's disease of bone treated with APD. Stone, M.D., Marshall, D.H., Hosking, D.J., Perkins, A.C., Evans, A.J., Wastie, M.L. J. Bone Miner. Res. (1992) [Pubmed]
  29. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone. O'Doherty, D.P., Gertz, B.J., Tindale, W., Sciberras, D.G., Survill, T.T., Kanis, J.A. J. Bone Miner. Res. (1992) [Pubmed]
  30. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone. Ryan, P.J., Gibson, T., Fogelman, I. J. Nucl. Med. (1992) [Pubmed]
  31. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. Filipponi, P., Cristallini, S., Policani, G., Casciari, C., Gregorio, F. Bone (1998) [Pubmed]
WikiGenes - Universities